EUVIMEDEUVIMED entdecken
Open Access

Diagnostic Value of Routine Delayed Pelvic Imaging for Patients with Biochemical Recurrence of Prostate Cancer Undergoing 68 Ga-PSMA PET/CT

Karen Y Jia, Jonathan Kuten, Heather Y Jia, Eric H Bent, Patrick Silveira, Luca Pasquini, Sunny Nalavenkata, Heiko Schoder, Josef J Fox, Randy Yeh, Ali A Razmaria

Journal of Nuclear Medicine · 2026

DOI: 10.2967/jnumed.126.272009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2026. Verfasst von Karen Y Jia und 10 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; jiak@mskcc.org. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron Emission Tomography Computed Tomography, Oligopeptides, Organometallic Compounds. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The detection of biochemical recurrence (BCR) of prostate cancer remains challenging, as small-volume disease may fall below the sensitivity of standard imaging. Prostate-specific membrane antigen (PSMA) PET/CT is currently the most sensitive imaging modality for tumor detection at low prostate-specific antigen (PSA) levels, but recurrence continues to be difficult to detect. We evaluated whether routine delayed pelvic imaging at 90 min postinjection improves diagnosis of sites of recurrence in patients referred for BCR.

Methods

We retrospectively analyzed 201 patients with prostate cancer undergoing dual-phase 68Ga-PSMA PET/CT for BCR of prostate cancer (median PSA, 0.52 ng/mL). Imaging of vertex to midthighs was acquired at approximately 60 min and delayed pelvic imaging at approximately 90 min postinjection. Two nuclear medicine physicians independently assessed whether delayed imaging improved diagnostic certainty or revealed additional 68Ga-PSMA-avid lesions.

Results

Delayed pelvic imaging improved diagnostic certainty for 68 patients (34%) and revealed additional 68Ga-PSMA-avid lesions for 23 patients (11%). Of patients with additional lesions detected on delayed imaging, roughly one third-representing 3% of the total cohort-subsequently received focal radiation dose escalation during treatment planning. Improvements were primarily influenced by increased tracer uptake confirming subtle lesions, reduced bladder or ureteral interference, and differentiation of physiologic from pathologic uptake. All measurable lesions within the field of view of the delayed pelvic image were quantified. The median SUVmax for malignant lesions increased from 4.3 to 5.0, whereas benign lesions remained stable (median SUVmax of 2.7 on normal imaging and 2.6 on delayed imaging).

Conclusion

Routine delayed pelvic imaging at 90 min postinjection enhanced lesion detection and diagnostic confidence in BCR of prostate cancer, particularly at low (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsPositron Emission Tomography Computed TomographyOligopeptidesOrganometallic CompoundsEdetic AcidPelvisHumansMaleGallium IsotopesGallium RadioisotopesRetrospective StudiesAgedMiddle AgedAged, 80 and overTime FactorsRecurrenceNeoplasm Recurrence, Local

Stichwörter der Autor:innen

PSMA PET/CTbiochemical recurrencedelayed pelvic imagingdiagnostic certainty

Substanzen

Gallium IsotopesGallium Radioisotopesgallium 68 PSMA-11OligopeptidesOrganometallic CompoundsEdetic Acid

Autor:innen und Institutionen

  • Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; jiak@mskcc.org.
  • Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Faculty of Science, University of British Columbia, Vancouver, British Columbia, Canada.
  • Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; and.
  • Department of Radiology, Mount Sinai Hospital, New York, New York.

Förderung

  • NCI NIH HHS

Zitieren

APA

Jia, K. Y., Kuten, J., Jia, H. Y., Bent, E. H., Silveira, P., Pasquini, L., Nalavenkata, S., Schoder, H., Fox, J. J., Yeh, R., & Razmaria, A. A. (2026). Diagnostic Value of Routine Delayed Pelvic Imaging for Patients with Biochemical Recurrence of Prostate Cancer Undergoing 68 Ga-PSMA PET/CT. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.126.272009

Vancouver

Jia KY, Kuten J, Jia HY, Bent EH, Silveira P, Pasquini L, et al. Diagnostic Value of Routine Delayed Pelvic Imaging for Patients with Biochemical Recurrence of Prostate Cancer Undergoing 68 Ga-PSMA PET/CT. Journal of Nuclear Medicine. 2026. doi:10.2967/jnumed.126.272009

BibTeX
@article{Jia2026,
  author = {Jia, Karen Y and Kuten, Jonathan and Jia, Heather Y and Bent, Eric H and Silveira, Patrick and Pasquini, Luca and Nalavenkata, Sunny and Schoder, Heiko and Fox, Josef J and Yeh, Randy and Razmaria, Ali A},
  title = {Diagnostic Value of Routine Delayed Pelvic Imaging for Patients with Biochemical Recurrence of Prostate Cancer Undergoing 68 Ga-PSMA PET/CT},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  doi = {10.2967/jnumed.126.272009}
}
Kostenlos starten →